Straits Times Index
3,296.89 +4.20 (+0.13%) S&P 500
5,065.98 +47.59 (+0.95%) Dow
38,247.72 +344.43 (+0.91%) Nasdaq
15,838.93 +233.45 (+1.50%) Bitcoin USD
59,518.89 +598.82 (+1.02%) CMC Crypto 200
1,275.57 +4.83 (+0.38%)
AxoGen, Inc. (AXGN)
| Previous close | 6.56 |
| Open | 6.48 |
| Bid | 5.71 x 100 |
| Ask | 5.79 x 200 |
| Day's range | 5.61 - 7.08 |
| 52-week range | 3.45 - 10.83 |
| Volume | |
| Avg. volume | 375,229 |
| Market cap | 250.869M |
| Beta (5Y monthly) | 1.02 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.51 |
| Earnings date | 02 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 27 Jan 2010 |
| 1y target est | 13.67 |
ZacksAxoGen (AXGN) Reports Q1 Loss, Lags Revenue Estimates
AxoGen (AXGN) delivered earnings and revenue surprises of 40% and 1.60%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewswireAxogen, Inc Reports First Quarter 2024 Financial Results
ALACHUA, Fla. and TAMPA, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2024. First Quarter Financial Results First quarter revenue was $41.4 million, a 12.9% increase compared to the first quarter of 2023.In the first quarter of 2024, our gross margin increased to 78.8%, up fro
Simply Wall St.AxoGen, Inc. (NASDAQ:AXGN) is largely controlled by institutional shareholders who own 58% of the company
Key Insights Institutions' substantial holdings in AxoGen implies that they have significant influence over the...
